Yale Cancer Center Researchers Discover Differences in Response for Endometrial Cancer Treated With Pembrolizumab
October 28, 2022
October 28, 2022
NEW HAVEN, Connecticut, Oct. 28 (TNSjou) -- Yale School of Medicine issued the following news:
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
The findings were published today in the j . . .
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
The findings were published today in the j . . .